Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and ...

The European Commission approved up to €403 million ($472 million) in funding to support development of innovations in ...

After a tough few weeks for Sarepta Therapeutics Inc., the EMA dealt another blow on July 25, announcing it will not be ...

Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, ...

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received ...

Thirty-six biotechnology, pharmaceutical and medical device companies sought a capital raise on the Hong Kong Stock Exchange in the first half (H1) of 2025, a review by BioWorld found. Of those, 34 ...

Brandon Capital Partners Pty Ltd., Australia’s largest life sciences venture capital firm, announced the final close of its sixth fund at AU$439 million (US$288 million), the VC’s largest fund to date ...

Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to ...

The combination of interleukin-2 (IL-2) agonism with programmed cell death protein 1 (PD-1) checkpoint inhibition has ...

The Trump administration released an action plan for AI, which includes an exports program for full-stack AI in areas such as ...

The human genome has yielded another round of secrets with the publication of two back-to-back papers in Nature on July 23, 2025. Both studies re-sequenced probands from the open-access 1000 Genomes ...

Astrazeneca plc seems on the way to expanding its presence in myasthenia gravis (MG) with positive “high-level” results from ...